Systemic interleukin 1β inhibition in proliferative diabetic retinopathy: A prospective open-label study using canakinumab

Retina

Volumn 36, Issue 2, 2016, Pages 385-391

  Stahel, Marc ^a   Becker, Matthias ^a,b   Graf, Nicole ^c   Michels, Stephan ^a,d  

^a TRIEMLI HOSPITAL   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Graf Biostatistics   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

antiangiogenic; canakinumab; diabetic retinopathy; edema; interleukin; neovascularization

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PILOT STUDY; PROLIFERATIVE DIABETIC RETINOPATHY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RETINA EDEMA; RETINA FOVEA; RETINA NEOVASCULARIZATION; SYSTEMIC THERAPY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETIC RETINOPATHY; FLUORESCENCE ANGIOGRAPHY; INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL NEOVASCULARIZATION; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-1BETA; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINAL NEOVASCULARIZATION; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84957631835     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000701     Document Type: Article

References (21)

1. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-553.
2. Ramachandran A, Mary S, Yamuna A, et al. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care 2008;31:893-898.
3. Dhimolea E. Canakinumab. MAbs 2010;2:3-13.
4. Maedler K, Sergeev P, Ris F, et al. Glucose-induced b-cell production of IL-1b contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-860.
5. Schumann DM, Maedler K, Franklin I, et al. The Fas pathway is involved in pancreatic beta cell secretory function. Proc Natl Acad Sci U S A 2007;104:2861-2866.
6. Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012;35:1654-1662.
7. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-recep-tor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526.
8. Howard C, Noe A, Skerjanec A, et al. Safety and tolerability of canakinumab, an IL-1b inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol 2014;13:94.
9. Patel JI, Saleh GM, Hykin PG, et al. Concentration of haemo-dynamic and inflammatory related cytokines in diabetic reti-nopathy. Eye (Lond) 2008;22:223-228.
10. Demircan N, Safran BG, Soylu M, et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006;20:1366-1369.
11. Lu P, Li L, Liu G, et al. Enhanced experimental corneal neo-vascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist. Invest Ophthalmol Vis Sci 2009;50:4761-4768.
12. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevaci-zumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
13. McNatt LG, Weimer L, Yanni J, Clark AF. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther 1999;15: 413-423.
14. Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol 2004; 88:1343-1347.
15. Geitzenauer W, Michels S, Prager F, et al. Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study. Retina 2008;28:1375-1386.
16. Galfrascoli E, Piva S, Cinquini M, et al. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 2011;43:286-294.
17. Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014;9: CD011230.
18. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-983.
19. Ikonomidis I, Tzortzis S, Andreadou I, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging 2014;7:619-628.
20. Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1b inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012;126: 2739-2748.
21. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1b inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605.